Abbott India (ABBOTINDIA)₹26,680−0.02%Pharmaceuticals
In the Mar 2026 quarter (standalone), Abbott India reported sales of ₹1,705 Cr, up 6.4% from Mar 2025, and net profit of ₹396 Cr, up 7.6% year on year. For the year to Mar 2026, sales were ₹6,909 Cr and net profit ₹1,554 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,475 | 1,490 | 1,434 | 1,436 | 1,553 | 1,630 | 1,610 | 1,602 | 1,735 | 1,752 | 1,719 | 1,705 |
| Expenses | 1,122 | 1,112 | 1,049 | 1,108 | 1,166 | 1,193 | 1,177 | 1,175 | 1,293 | 1,254 | 1,260 | 1,228 |
| Operating Profit | 354 | 380 | 387 | 329 | 390 | 437 | 434 | 427 | 445 | 500 | 461 | 479 |
| OPM % | 24.0% | 25.0% | 27.0% | 23.0% | 25.0% | 27.0% | 27.0% | 27.0% | 26.0% | 29.0% | 27.0% | 28.0% |
| Other Income | 55.97 | 55.93 | 55.90 | 80.90 | 66.92 | 59.91 | 71.94 | 75.90 | 72.87 | 69.89 | 69.94 | 75.91 |
| Interest | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 1.99 | 1.99 | 3.99 | 5.99 | 7.98 | 4.99 | 5.98 |
| Depreciation | 16.94 | 17.93 | 17.94 | 17.95 | 17.93 | 17.95 | 17.93 | 17.94 | 18.92 | 18.93 | 18.92 | 18.95 |
| Profit before tax | 389 | 413 | 420 | 389 | 435 | 477 | 486 | 482 | 491 | 544 | 507 | 529 |
| Tax % | 26.1% | 25.1% | 26.0% | 26.0% | 25.1% | 25.1% | 26.1% | 24.0% | 26.0% | 24.0% | 26.1% | 26.1% |
| Net Profit | 290 | 313 | 312 | 287 | 328 | 360 | 361 | 368 | 367 | 416 | 377 | 396 |
| EPS (Rs) | 136.30 | 146.87 | 145.91 | 134.85 | 154.04 | 168.46 | 169.52 | 172.28 | 171.77 | 194.87 | 176.56 | 185.30 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,609 | 2,897 | 3,288 | 3,673 | 4,084 | 4,302 | 4,909 | 5,333 | 5,838 | 6,396 | 6,909 | 6,911 |
| Expenses | 2,247 | 2,505 | 2,774 | 3,074 | 3,336 | 3,386 | 3,829 | 4,140 | 4,392 | 4,711 | 5,033 | 5,035 |
| Operating Profit | 363 | 396 | 523 | 602 | 755 | 919 | 1,084 | 1,201 | 1,447 | 1,688 | 1,885 | 1,885 |
| OPM % | 14.0% | 14.0% | 16.0% | 16.0% | 18.0% | 21.0% | 22.0% | 23.0% | 25.0% | 26.0% | 27.0% | 27.3% |
| Other Income | 49.89 | 56.89 | 117 | 113 | 114 | 80.83 | 76.87 | 154 | 248 | 275 | 288 | 289 |
| Interest | 2.99 | 1.99 | 3.99 | 1.99 | 8.99 | 17.96 | 18.95 | 15.96 | 11.97 | 10.97 | 24.93 | 24.94 |
| Depreciation | 13.94 | 15.96 | 15.95 | 16.93 | 59.83 | 57.79 | 65.81 | 69.71 | 70.80 | 71.76 | 75.79 | 75.72 |
| Profit before tax | 397 | 434 | 618 | 696 | 800 | 923 | 1,076 | 1,270 | 1,613 | 1,881 | 2,072 | 2,072 |
| Tax % | 36.0% | 37.1% | 35.1% | 36.1% | 26.0% | 25.0% | 26.1% | 25.1% | 26.0% | 25.0% | 25.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 5.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.99 | — |
| Net Profit | 255 | 277 | 402 | 450 | 594 | 692 | 799 | 951 | 1,202 | 1,416 | 1,554 | 1,554 |
| EPS (Rs) | 119.95 | 129.87 | 188.52 | 211.29 | 278.45 | 324.12 | 374.95 | 445.52 | 564.29 | 663.90 | 728.21 | 728.50 |
| Dividend payout % | 29.0% | 31.0% | 29.0% | 31.0% | 90.0% | 85.0% | 73.0% | 73.0% | 73.0% | 71.0% | 90.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.90 | 20.90 | 20.91 | 20.90 | 20.91 | 20.91 | 20.91 | 20.91 | 20.91 | 20.90 | 20.90 | 20.91 |
| Reserves | 914 | 1,172 | 1,363 | 1,668 | 1,982 | 2,402 | 2,575 | 2,791 | 3,161 | 3,666 | 4,199 | 4,742 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 174 | 153 | 152 | 113 | 82.72 | 196 | 172 |
| Other Liabilities | 434 | 419 | 676 | 720 | 928 | 935 | 1,081 | 1,247 | 1,248 | 1,404 | 1,480 | 1,549 |
| Total Liabilities | 1,370 | 1,612 | 2,060 | 2,409 | 2,932 | 3,533 | 3,828 | 4,210 | 4,544 | 5,174 | 5,896 | 6,483 |
| Fixed Assets | 95.84 | 108 | 110 | 80.83 | 105 | 269 | 251 | 271 | 237 | 224 | 335 | 331 |
| CWIP | 3.99 | 2.99 | 5.98 | 1.99 | 0.99 | 1.99 | 0.99 | 0.99 | 3.99 | 9.97 | 17.96 | 5.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 1,270 | 1,501 | 1,944 | 2,326 | 2,826 | 3,262 | 3,578 | 3,938 | 4,303 | 4,939 | 5,542 | 6,146 |
| Inventories | 385 | 371 | 503 | 587 | 609 | 529 | 720 | 690 | 651 | 622 | 885 | 950 |
| Trade receivables | 129 | 145 | 177 | 263 | 277 | 319 | 251 | 289 | 318 | 320 | 381 | 363 |
| Cash & equivalents | 645 | 840 | 1,093 | 1,032 | 1,687 | 2,201 | 2,413 | 2,753 | 1,940 | 2,137 | 1,628 | 2,260 |
| Total Assets | 1,370 | 1,612 | 2,060 | 2,409 | 2,932 | 3,533 | 3,828 | 4,210 | 4,544 | 5,174 | 5,896 | 6,483 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 214 | 248 | 306 | 152 | 497 | 624 | 725 | 945 | 890 | 1,208 | 1,009 | 1,315 |
| Cash from investing activity | −186 | −76.67 | −154 | −214 | −256 | −400 | −71.68 | −395 | −148 | −415 | 181 | −370 |
| Cash from financing activity | −57.86 | −79.81 | −89.77 | −102 | −143 | −217 | −581 | −635 | −637 | −742 | −922 | −1,063 |
| Net cash flow | −29.93 | 90.81 | 61.86 | −165 | 98.79 | 7.98 | 72.88 | −85.81 | 107 | 51.87 | 268 | −118 |
| Capex | 18.06 | 23.08 | 21.06 | 24.07 | 12.04 | 16.07 | 23.10 | 44.15 | 34.13 | 48.20 | 53.18 | 41.18 |
| Free cash flow | 199 | 226 | 287 | 180 | 503 | 610 | 703 | 902 | 859 | 1,164 | 959 | 1,305 |
| CFO / OP % | 106.1% | 109.1% | 117.1% | 68.1% | 125.1% | 113.0% | 104.0% | 114.1% | 102.0% | 111.1% | 86.1% | 98.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 | 19 |
| Inventory days | 108 | 92 | 108 | 113 | 107 | 84 | 111 | 95 | 81 | 71 | 93 | 95 |
| Days payable | 53 | 55 | 100 | 91 | 115 | 103 | 115 | 121 | 108 | 113 | 109 | 108 |
| Cash conversion cycle | 75 | 55 | 29 | 50 | 18 | 9 | 15 | −5 | −7 | −23 | 4 | 4 |
| Working capital days | 30 | 32 | 21 | 63 | 22 | 10 | 4 | −7 | −8 | −14 | 99 | 2 |
| ROCE % | 40.1% | 38.1% | 34.1% | 41.0% | 37.1% | 35.1% | 35.1% | 38.1% | 41.1% | 46.0% | 46.0% | 45.1% |
For the Mar 2026 quarter, Abbott India reported sales of ₹1,705 Cr, up 6.4% year on year and net profit of ₹396 Cr, up 7.6% year on year. The operating margin was 28.0%.
Abbott India's sales for the year to Mar 2026 were ₹6,909 Cr; over the last twelve months they were ₹6,911 Cr.
Net profit for the year to Mar 2026 was ₹1,554 Cr, and ₹1,554 Cr over the last twelve months. Earnings per share over the same trailing period were ₹728.50.
Abbott India reported borrowings of ₹172 Cr at Mar 2026, against cash and equivalents of ₹2,260 Cr.
Cash from operations was ₹1,315 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹1,305 Cr.